Natera

Historical price data

Natera's mission is to transform the management of cancer, pregnancy, and organ transplantation through advanced cell-free DNA analysis. The company has achieved a dominant position in minimal residual disease (MRD) testing with its Signatera™ assay, supported by over 400 peer-reviewed publications and a database of over 350,000 de-identified patient records. Its strategy centers on expanding its technology platform through acquisitions like Foresight Diagnostics, commercializing new tests like Zenith™ for rare disease, and leveraging its massive real-world data to accelerate biopharma partnerships and clinical adoption.

Proprietary, ultra-sensitive cell-free DNA (cfDNA) analysis platform enabling detection below 0.1 parts per million, supporting both tumor-informed and tissue-free assay architectures for minimal residual disease, prenatal genetics, transplant rejection, and rare disease diagnosis.

Natera competes with Guardant Health, CareDx, and large reference labs like Labcorp and Quest across its segments. Its primary competitive advantages are its extensive clinical validation in early-stage cancer, industry-leading sensitivity from its phased-variant technology, and its proprietary, multimodal real-world data database.